Browse the evidence

Pharmacological treatment of obesity is ineffective and potentially harmful if not combined with lifestyle changes (calorie restriction and increased energy expenditure), as evidenced by 'stop rules' that mandate discontinuation if <5% weight loss occurs within 12 weeks.

Obesity drugs are not magic. They require you to eat less and move more. If you don't see at least 5% weight loss in 3 months on the full dose, the drug isn't working for you, and you should stop and try something else. Always combine medication with lifestyle changes for the best results.

Tirzepatide produces superior weight loss and glycemic control compared to GLP-1 receptor agonists (e.g., semaglutide) by acting as a balanced dual GIP/GLP-1 receptor agonist, leveraging GIP-mediated effects on adipose tissue metabolism and insulin sensitivity.

Tirzepatide is a once-weekly injectable medication that targets both GLP-1 and GIP receptors. It has been shown to produce significant weight loss (up to 25% in some trials) and improve blood sugar control, often outperforming GLP-1-only drugs. It is prescribed for obesity and type 2 diabetes under medical supervision.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant, sustained weight loss (5-20% body weight reduction) in adults with obesity or overweight with comorbidities, primarily by delaying gastric emptying and reducing central appetite signaling.

If you have obesity or overweight with related health issues, GLP-1 medications like semaglutide or tirzepatide are currently the most effective pharmacological tools available in Europe. They work by mimicking hormones that tell your brain you are full and slowing down digestion. While they require weekly injections and may cause temporary stomach issues, they can lead to significant, sustained weight loss (often 15% or more) when combined with diet and exercise changes. Older weight loss drugs are largely unavailable due to safety risks.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) produces significantly greater weight loss and glycemic control than semaglutide (a GLP-1 receptor agonist) in patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, tirzepatide (Mounjaro/Zepbound) is clinically shown to be more effective for weight loss and blood sugar control than semaglutide (Ozempic/Wegovy). It works by targeting two hormones (GLP-1 and GIP) rather than just one. Expect weekly injections and potential stomach upset initially, which usually improves as your dose increases. Consult your doctor to see if this stronger option is appropriate for your specific health profile.

Subcutaneous semaglutide 2.4 mg administered once weekly reduces the risk of death from cardiovascular causes by 20% in patients with overweight or obesity without diabetes, based on the SELECT trial.

If you have had a heart attack and are overweight or obese but do not have diabetes, ask your doctor about semaglutide 2.4 mg. It is taken once weekly and has been shown to significantly reduce the risk of dying from heart-related causes. Be aware of potential stomach issues and the high cost if not covered by insurance.

Bariatric surgery (Roux-en-Y or Sleeve Gastrectomy) provides superior long-term weight loss and metabolic remission compared to conservative lifestyle interventions alone.

If you have severe obesity and metabolic syndrome, lifestyle changes alone rarely sustain weight loss long-term. Bariatric surgery (like Sleeve or Gastric Bypass) is the most effective treatment, offering nearly 20% total body weight loss and high rates of diabetes/blood pressure remission that diet alone cannot achieve.

Continuous administration of GLP-1/GIP receptor agonists (liraglutide, semaglutide, tirzepatide) produces significant weight loss (6-22%) and cardiovascular risk reduction, but discontinuation leads to rapid weight regain and loss of therapeutic benefits.

Obesity pharmacotherapy with GLP-1/GIP agonists is highly effective for weight loss and cardiovascular health, but it is not a 'cure' with a fixed end date. You must continue the medication long-term to maintain weight loss; stopping leads to rapid regain. Discuss with your doctor whether the benefits of continuous therapy outweigh the burden of daily/weekly injections and potential side effects.

GLP-1 and dual/triple agonist therapies (semaglutide, tirzepatide, retatrutide) produce double-digit mean weight loss (15-24%) in clinical trials, significantly exceeding older pharmacotherapies.

If you have obesity, newer GLP-1 or dual/triple agonist medications can help you lose 15-20% of your body weight, which is significantly more than older drugs. These are taken as weekly injections (or soon, oral pills). You must discuss insurance coverage and potential side effects like nausea with your doctor, as cost and access are major hurdles.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce substantial weight loss (10-25%) and improve glycemic control through appetite suppression and enhanced satiety.

GLP-1 and GIP/GLP-1 agonists are highly effective for weight loss, achieving 10-25% reduction. They work by suppressing appetite and increasing satiety. Treatment requires a gradual dose increase to manage common gastrointestinal side effects like nausea. These drugs are indicated for adults with obesity or overweight with comorbidities, and should be used alongside lifestyle changes.

At maximum approved doses, tirzepatide (15 mg) produces significantly greater weight loss and glycemic improvement than semaglutide (2.4 mg).

If you are treating obesity with GLP-1/GIP agonists at their maximum FDA-approved doses, Tirzepatide (15 mg) will likely produce more weight loss and better blood sugar control than Semaglutide (2.4 mg). However, cost and availability may make Semaglutide a more practical first choice for some patients.

Modern incretin-based and multi-agonist peptide therapies (GLP-1, GIP/GLP-1, and triple agonists) induce double-digit percentage weight loss (15-25%) that approaches or exceeds outcomes historically associated with bariatric surgery.

If you have obesity, modern peptide therapies like tirzepatide or semaglutide can help you lose 15-25% of your body weight, which is significantly more than older drugs and approaches the results of surgery. These treatments work by targeting the hormones that control your hunger and metabolism. While they are injectable and can be expensive, they are increasingly considered first-line treatments, especially if you have other health risks like heart disease or diabetes. You should discuss these options with your doctor to see if they are appropriate for you.

Semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE) in individuals with overweight or obesity without diabetes, establishing pharmacological weight loss as cardiovascular risk-modifying therapy.

If you have overweight or obesity but no diabetes, semaglutide 2.4 mg can help reduce your risk of serious heart problems like heart attack and stroke. This benefit is independent of your blood sugar levels. It is an injectable medication taken once a week. You should talk to your doctor about whether this is right for you, especially if you have other cardiovascular risk factors.

Semaglutide (2.4 mg weekly) significantly improves MASH resolution and fibrosis in patients with F2-F3 fibrosis, with benefits extending to significant weight loss and metabolic improvements.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Semaglutide is a new once-weekly injection option. It significantly reduces liver inflammation and scarring, and also promotes weight loss and improves blood sugar and cholesterol. It is generally well-tolerated, though gastrointestinal side effects are common initially.

Semaglutide 2.4 mg/week significantly reduces major adverse cardiovascular events (MACE) in overweight or obese adults with preexisting cardiovascular disease but without diabetes.

If you are overweight or obese and have existing heart disease but no diabetes, ask your doctor about semaglutide 2.4 mg/week. It is the first obesity medication proven to lower the risk of heart attacks, strokes, and cardiovascular death. The treatment involves a weekly injection, starting at a low dose to minimize stomach issues, and has been shown to significantly improve cardiovascular outcomes over standard care alone.

Semaglutide 2.4 mg/week leads to significant weight loss and improvement in cardiovascular risk factors (blood pressure, lipids, inflammation) in overweight or obese adults without diabetes.

Semaglutide 2.4 mg/week helps overweight or obese individuals lose an average of 9.4% of their body weight over 104 weeks, compared to less than 1% with placebo. This weight loss is associated with improvements in blood pressure, cholesterol, and inflammation markers, contributing to better cardiovascular health.

Semaglutide 2.4 mg/week significantly reduces the incidence of new-onset type 2 diabetes and prediabetes in overweight or obese adults without diabetes.

For overweight or obese individuals without diabetes, semaglutide 2.4 mg/week reduces the risk of developing type 2 diabetes by 73% and prediabetes by 67% compared to placebo.

Weight loss interventions, particularly pharmacologic treatments like GLP-1 receptor agonists (e.g., semaglutide, tirzepatide), significantly reduce OSA severity and may reduce cardiovascular disease risk.

If you have sleep apnea and are overweight, losing weight is one of the most powerful things you can do for your heart and your sleep. Modern medications like semaglutide or tirzepatide can help you lose significant weight, which directly reduces the severity of your sleep apnea and your risk of heart disease. Discuss these options with your doctor.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.

If you have obesity and cardiovascular risk factors, GLP-1 agonists like semaglutide or liraglutide are highly effective. They help you lose significant weight and reduce your risk of heart attacks and strokes. These are typically injected weekly or daily. Discuss with your doctor if you are a candidate, especially if you have obesity-related complications.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces substantial, sustained, and dose-dependent weight loss in adults with obesity, significantly outperforming placebo, semaglutide, and dulaglutide.

If you have obesity, Tirzepatide is a highly effective, once-weekly injection that helps you lose a significant amount of weight (up to 20% or more) by targeting the hormones that control hunger and fullness. It works better than other similar drugs and lifestyle changes alone. While it can cause temporary stomach issues like nausea, these usually get better over time. It is a long-term treatment for a chronic condition.

GLP-1 receptor agonists (Liraglutide 3.0 mg and Semaglutide 2.4 mg) produce superior weight loss and cardiovascular risk reduction compared to other pharmacotherapies, making them first-line pharmacological options for high-risk patients.

If lifestyle changes alone are insufficient, GLP-1 medications like Semaglutide or Liraglutide are the most effective pharmacological options, offering significant weight loss (up to 12+ kg) and cardiovascular benefits. They require weekly or daily injections and slow dose titration to manage side effects. Discuss cost and insurance coverage with your provider to determine if this is a viable long-term strategy.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce superior weight loss (>10% initial body weight) compared to other approved anti-obesity medications by acting centrally to increase satiety and reduce appetite.

If lifestyle changes alone haven't worked, GLP-1 agonists like semaglutide or tirzepatide are the most effective pharmacological options, capable of producing over 10% weight loss. These require weekly injections and a gradual dose titration to manage side effects like nausea.

Liraglutide and semaglutide are the only approved anti-obesity medications demonstrated to lower the risk of major cardiovascular events in patients with or without established cardiovascular disease.

For patients with obesity and existing heart disease or diabetes, Liraglutide (3mg daily) and Semaglutide (2.4mg weekly) are preferred because they reduce cardiovascular event risk, unlike other weight loss drugs.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss in adults and adolescents with obesity by delaying gastric emptying, suppressing appetite via central satiety pathways, and stimulating glucose-dependent insulin secretion.

GLP-1 and GIP medications (like semaglutide and tirzepatide) are highly effective for weight loss, achieving 15-20% body weight reduction in clinical trials. They work by slowing digestion and reducing hunger signals in the brain. Treatment involves weekly or daily injections with gradual dose increases to minimize stomach upset. These drugs are most effective when combined with a calorie-controlled diet and regular physical activity.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (up to 2.6%) and body weight (up to 12.9 kg) in Type 2 Diabetes patients, outperforming existing GLP-1 agonists and insulin.

Tirzepatide is a once-weekly injectable medication for Type 2 Diabetes that works by mimicking two gut hormones (GIP and GLP-1). It is highly effective at lowering blood sugar and promoting significant weight loss, often outperforming other common diabetes medications. Patients should expect a gradual dose increase to minimize stomach upset, and pharmacists play a key role in managing side effects and ensuring adherence.